Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04225871 · ClinicalTrials.gov registry record · Phase 3
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
A Phase 3 study of Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL.
- Active
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT04225871 is a Phase 3 study of Generalized Myasthenia Gravis that is active but no longer recruiting, run by UCB Biopharma SRL. The registered enrollment target is 200 participants, above the 123-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (63% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT04225871, a Phase 3 study of Generalized Myasthenia Gravis, is active but no longer recruiting, sponsored by UCB Biopharma SRL.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.
Conditions Studied
Interventions
- DRUG zilucoplan (RA101495)
Study Locations (20)
California
- Mg0011 31 - Irvine
- MG0011 4 - Los Angeles
- Mg0011 220 - Pasadena
- Mg0011 160 - San Francisco
New York
- Mg0011 30 - Buffalo
- Mg0011 123 - Great Neck
- Mg0011 23 - New York
Michigan
- Mg0011 33 - Detroit
- Mg0011 49 - East Lansing
Alabama
- Mg0011 41 - Mobile
Arizona
- Mg0011 116 - Phoenix
Connecticut
- Mg0011 24 - New Haven
District of Columbia
- Mg0011 27 - Washington D.C.
Florida
- Mg0011 25 - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2019-12-23 |
| Est. Completion | 2026-06-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04225871
The ClinicalTrials.gov registry entry for NCT04225871 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 123-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (63% higher). The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 1 intervention - of which zilucoplan (RA101495) is the first listed.
NCT04225871 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, New York, Michigan.
Frequently Asked Questions
What is clinical trial NCT04225871 about?
NCT04225871 is a clinical study titled "Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis". The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.
What is the current status of trial NCT04225871?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2019-12-23. Estimated completion is 2026-06-02.
What conditions does trial NCT04225871 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis.
What interventions are being tested in trial NCT04225871?
The interventions under investigation include: zilucoplan (RA101495) (DRUG).
Who is sponsoring clinical trial NCT04225871?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04225871 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
RECRUITING · Phase 3
-
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.